Search results
Results From The WOW.Com Content Network
The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).
Necrotizing pneumonia (NP), also known as cavitary pneumonia or cavitatory necrosis, is a rare but severe complication of lung parenchymal infection. [1] [2] [3] In necrotizing pneumonia, there is a substantial liquefaction following death of the lung tissue, which may lead to gangrene formation in the lung. [4] [5] In most cases patients with ...
[3] [10] Serologic studies have shown that by the age of five, virtually all children worldwide have been exposed to the virus. [2] [11] [12] [13] Despite near universal infection during early life, reinfections are common in older children and adults. [3] [14] [12] [15] Human metapneumovirus may cause mild upper respiratory tract infection ...
Pneumococcal vaccine. 23-valent pneumococcal polysaccharide vaccine by MSD as it is marketed in Japan. Pneumococcal vaccines are vaccines against the bacterium Streptococcus pneumoniae. [ 1] Their use can prevent some cases of pneumonia, meningitis, and sepsis. [ 1] There are two types of pneumococcal vaccines: conjugate vaccines and ...
US FDA approves Merck's pneumococcal vaccine for adults. June 17, 2024 at 5:52 PM. (Reuters) -Merck said on Monday the U.S. Food and Drug Administration has approved its next-generation vaccine to ...
Viral pneumonia. Specialty. Infectious disease, respirology. Viral pneumonia is a pneumonia caused by a virus. Pneumonia is an infection that causes inflammation in one or both of the lungs. The pulmonary alveoli fill with fluid or pus making it difficult to breathe. [ 1] Pneumonia can be caused by bacteria, viruses, fungi or parasites. [ 1]
Prevnar vaccine. Prevnar 20 (PCV20) is the third version of a vaccine produced by the Wyeth subsidiary of Pfizer.In April 2023, the FDA approved Prevnar 20 for the prevention of invasive disease caused by the 20 different serotypes of S. pneumoniae contained in the vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) for individuals 6 ...
Recombinant technology has however been used to target the formation of vaccines for HPIV-1, -2 and -3 and has taken the form of several live-attenuated intranasal vaccines. Two vaccines in particular were found to be immunogenic and well tolerated against HPIV-3 in phase I trials. HPIV-1 and -2 vaccine candidates remain less advanced.